Clinical Biochemistry — MCQs
On this page
Which of the following conditions masks low serum haptoglobin in hemolysis?
Which of the following vitamin deficiencies is found in patients with gastric cancer?
In carcinoma prostate with metastasis, which of the following biochemical markers is typically elevated?
Which cardiac marker is elevated earliest in myocardial infarction?
Which carbohydrate tumor marker is associated with breast cancer?
In hepatic cirrhosis, which of the following protein fractions is typically increased in serum electrophoresis?
Which serum marker is the last to return to normal levels following a myocardial infarction?
A patient presents with unconjugated hyperbilirubinemia and presence of urobilinogen in urine. Which amongst the following is the least likely diagnosis?
Increased 5-hydroxyindoleacetic acid in urine is seen in which of the following conditions?
Quantitative assessment of liver function can be done by:
Clinical Biochemistry Indian Medical PG Practice Questions and MCQs
Question 1: Which of the following conditions masks low serum haptoglobin in hemolysis?
- A. Bile duct obstruction (Correct Answer)
- B. Liver disease
- C. Malnutrition
- D. Pregnancy
Explanation: **Explanation:** The primary clinical utility of **Haptoglobin** is as a marker for **intravascular hemolysis**. Haptoglobin is an acute-phase reactant synthesized by the liver that binds free hemoglobin. During hemolysis, haptoglobin levels drop significantly as it is cleared by the reticuloendothelial system. **Why Bile Duct Obstruction is correct:** Haptoglobin is a **positive acute-phase reactant**. In conditions like **bile duct obstruction (obstructive jaundice)**, inflammation or biliary stasis triggers an increase in the hepatic synthesis of haptoglobin. This elevation can artificially "mask" or normalize the low levels typically seen in hemolysis, leading to a false-negative result for hemolytic anemia. **Analysis of Incorrect Options:** * **Liver Disease:** Since haptoglobin is synthesized in the liver, severe liver disease (e.g., cirrhosis) leads to **decreased** production. This would mimic or exacerbate low levels rather than masking them. * **Malnutrition:** Protein-energy malnutrition leads to a generalized decrease in plasma protein synthesis, including haptoglobin, resulting in **low** levels. * **Pregnancy:** Pregnancy is associated with a physiological decrease in haptoglobin levels (estrogen effect), which would not mask a hemolytic state. **NEET-PG High-Yield Pearls:** * **Gold Standard for Hemolysis:** A **decreased** serum haptoglobin level is one of the most sensitive markers for confirming hemolysis. * **Acute Phase Reactants:** Remember that haptoglobin levels rise in infection, trauma, and malignancy, which can confound the diagnosis of co-existing hemolysis. * **Neonate Fact:** Haptoglobin levels are naturally very low or absent in newborns (physiologic ahaptoglobinemia) and reach adult levels by 6 months of age.
Question 2: Which of the following vitamin deficiencies is found in patients with gastric cancer?
- A. Vitamin C
- B. Vitamin B12 (Correct Answer)
- C. Vitamin A
- D. Vitamin D
Explanation: **Explanation:** The correct answer is **Vitamin B12**. **Why Vitamin B12 is the correct answer:** Gastric cancer often involves the destruction or surgical resection of the gastric mucosa, specifically the **parietal cells** located in the body and fundus of the stomach. These cells are responsible for secreting **Intrinsic Factor (IF)**. Vitamin B12 (cobalamin) requires IF to form a complex that survives the acidic environment of the stomach and allows for absorption in the **terminal ileum**. In gastric cancer, the loss of parietal cells leads to IF deficiency, resulting in secondary Vitamin B12 malabsorption and potentially megaloblastic anemia (pernicious-like state). Additionally, the achlorhydria (lack of HCl) associated with gastric atrophy prevents the release of B12 from dietary proteins. **Why the other options are incorrect:** * **Vitamin C:** While low levels are associated with an increased *risk* of developing gastric cancer due to reduced antioxidant protection, the cancer itself does not characteristically cause a deficiency through a specific physiological mechanism like B12. * **Vitamin A & D:** These are fat-soluble vitamins. Their deficiency is typically associated with fat malabsorption syndromes (e.g., pancreatic insufficiency, biliary obstruction, or celiac disease) rather than the specific loss of gastric intrinsic factor. **High-Yield Clinical Pearls for NEET-PG:** * **Site of Absorption:** Vitamin B12 is absorbed in the **terminal ileum**, while Iron is absorbed in the **duodenum**. * **Post-Gastrectomy:** Patients undergoing total gastrectomy for gastric cancer *must* receive lifelong parenteral Vitamin B12 supplementation. * **Schilling Test:** Historically used to differentiate between causes of B12 deficiency (though largely replaced by antibody testing and metabolite levels). * **Associated Finding:** Look for **hypersegmented neutrophils** on a peripheral smear in patients with B12 deficiency.
Question 3: In carcinoma prostate with metastasis, which of the following biochemical markers is typically elevated?
- A. Erythrocyte Sedimentation Rate (ESR)
- B. Alkaline Phosphatase (Correct Answer)
- C. Acid Phosphatase
- D. Bilirubin
Explanation: **Explanation:** The correct answer is **Alkaline Phosphatase (ALP)**. In the context of prostate carcinoma, elevation of ALP is a hallmark of **osteoblastic (bone-forming) metastasis**. When prostate cancer cells spread to the bone, they stimulate osteoblasts to lay down new mineralized bone. ALP is a byproduct of osteoblastic activity; hence, its serum levels rise significantly as a marker of bone remodeling and turnover. **Analysis of Options:** * **Alkaline Phosphatase (Correct):** It is the most sensitive marker for detecting osteoblastic skeletal metastases in prostate cancer patients. * **Acid Phosphatase (Incorrect):** Specifically, Prostatic Acid Phosphatase (PAP) was historically used to diagnose prostate cancer. However, it is a marker of the **primary tumor burden** and soft tissue extension rather than bone metastasis specifically. It has largely been replaced by PSA (Prostate-Specific Antigen) in modern practice. * **ESR (Incorrect):** While ESR may be elevated in chronic malignancies or inflammation, it is a non-specific marker and not a diagnostic biochemical indicator for metastatic prostate cancer. * **Bilirubin (Incorrect):** Bilirubin is a marker of hepatobiliary disease or hemolysis and is not typically elevated in prostate cancer unless there is extensive, rare liver metastasis. **High-Yield Clinical Pearls for NEET-PG:** 1. **PSA (Prostate-Specific Antigen):** The most sensitive and specific marker for screening, monitoring, and detecting recurrence of prostate cancer. 2. **Osteoblastic vs. Osteolytic:** Prostate cancer typically causes **osteoblastic** lesions (High ALP), whereas Multiple Myeloma causes **osteolytic** lesions (Normal ALP). 3. **Acid Phosphatase:** If the question asks for a marker that correlates with the *volume* of the primary tumor or extra-capsular spread, PAP is the traditional answer.
Question 4: Which cardiac marker is elevated earliest in myocardial infarction?
- A. CPK-MB
- B. LDH
- C. Myoglobin (Correct Answer)
- D. Troponin I
Explanation: **Explanation:** The correct answer is **Myoglobin**. In the setting of an acute myocardial infarction (AMI), the timing of marker release depends on the molecule's size and its location within the cardiac cell. **1. Why Myoglobin is correct:** Myoglobin is a small heme protein found in the cytosol. Due to its low molecular weight, it is released rapidly into the bloodstream following membrane damage. It is the **earliest marker** to rise, typically appearing within **1–3 hours** of symptom onset and peaking at 6–9 hours. Its high sensitivity makes it excellent for "ruling out" an MI in the early stages if levels remain normal. **2. Why the other options are incorrect:** * **CPK-MB:** This isoenzyme begins to rise **4–6 hours** after injury. While it was previously the gold standard, it is now primarily used to detect **re-infarction** because it returns to baseline quickly (within 48–72 hours). * **Troponin I:** These are the most **specific** markers for cardiac injury. However, they begin to rise **3–6 hours** after the event, slightly later than myoglobin. They remain elevated for 7–10 days. * **LDH (Lactate Dehydrogenase):** This is a late marker. It begins to rise after **24 hours**, peaks at 3–4 days, and can stay elevated for up to 2 weeks. **High-Yield Clinical Pearls for NEET-PG:** * **Earliest Marker:** Myoglobin. * **Most Specific Marker:** Troponin I or T (Gold Standard). * **Marker for Re-infarction:** CPK-MB. * **Late Marker:** LDH (specifically the LDH-1 > LDH-2 "flipped pattern"). * **Window Period:** If a patient presents 12 hours after chest pain, Troponins are the most reliable; if they present within 2 hours, Myoglobin is the most sensitive.
Question 5: Which carbohydrate tumor marker is associated with breast cancer?
- A. CA 15-3 (Correct Answer)
- B. CA 125
- C. CA 34
- D. CA 19-9
Explanation: **Explanation:** **CA 15-3 (Cancer Antigen 15-3)** is the correct answer. It is a carbohydrate antigen derived from the **MUC1 gene** product. In clinical practice, it is primarily used as a tumor marker for **breast cancer**. While it is not sensitive enough for screening early-stage disease, it is highly valuable for monitoring treatment response and detecting the recurrence or metastasis of breast malignancy. **Analysis of Incorrect Options:** * **CA 125:** This is the classic marker for **Ovarian Cancer** (specifically non-mucinous epithelial tumors). It can also be elevated in endometriosis, pelvic inflammatory disease, and pregnancy. * **CA 34:** This is not a standard clinical tumor marker used in the NEET-PG curriculum. It is likely a distractor. (Note: CD34 is a marker for hematopoietic stem cells and vascular endothelium). * **CA 19-9:** This is the primary marker for **Pancreatic Cancer** and cholangiocarcinoma. It is also associated with other gastrointestinal malignancies and obstructive jaundice. **High-Yield Clinical Pearls for NEET-PG:** * **CA 27-29:** Another marker frequently associated with breast cancer, often used interchangeably with CA 15-3. * **CEA (Carcinoembryonic Antigen):** While most famous for colorectal cancer, it is the second most common marker used to monitor breast cancer. * **HER2/neu:** A proto-oncogene (not a carbohydrate marker) used to determine prognosis and eligibility for Trastuzumab therapy in breast cancer patients. * **AFP (Alpha-fetoprotein):** Marker for Hepatocellular Carcinoma (HCC) and Yolk Sac Tumors. * **PSA (Prostate Specific Antigen):** Marker for Prostate Cancer.
Question 6: In hepatic cirrhosis, which of the following protein fractions is typically increased in serum electrophoresis?
- A. Alpha 1 globulin
- B. Alpha 2 globulin
- C. Gamma globulin (Correct Answer)
- D. All of the above
Explanation: ### Explanation In hepatic cirrhosis, the serum protein electrophoresis (SPEP) pattern undergoes characteristic changes due to impaired liver synthetic function and chronic immune stimulation. **Why Gamma globulin is correct:** The increase in gamma globulins (polyclonal gammopathy) is a hallmark of cirrhosis. This occurs because the cirrhotic liver fails to effectively clear bacterial antigens and endotoxins from the portal circulation (due to portosystemic shunting). These antigens reach the systemic lymphoid tissue, triggering a broad immune response and increased production of antibodies (IgA, IgG, and IgM) by plasma cells. A classic diagnostic finding in cirrhosis is **"Beta-Gamma bridging,"** where the distinction between the beta and gamma peaks disappears because of increased IgA levels. **Why other options are incorrect:** * **Alpha 1 and Alpha 2 globulins:** These fractions primarily contain acute-phase reactants (like Alpha-1 antitrypsin and Haptoglobin) synthesized by the liver. In chronic liver disease/cirrhosis, the liver's synthetic capacity is diminished, leading to a **decrease** or normal levels of these proteins, rather than an increase. * **Albumin (not listed but relevant):** Albumin is synthesized exclusively by the liver. In cirrhosis, the albumin peak is significantly **decreased** (hypoalbuminemia), which is a key indicator of the severity of liver dysfunction. **High-Yield Clinical Pearls for NEET-PG:** * **Beta-Gamma Bridging:** Pathognomonic SPEP finding for hepatic cirrhosis (specifically due to IgA elevation). * **Negative Acute Phase Reactant:** Albumin levels drop during inflammation and liver disease. * **A/G Ratio:** In cirrhosis, the Albumin/Globulin (A/G) ratio is **reversed** (normally 1.5:1 to 2.5:1) because albumin decreases while globulins increase. * **Alpha-1 Antitrypsin Deficiency:** If the Alpha-1 peak is specifically absent/low in a patient with liver disease, consider genetic AAT deficiency.
Question 7: Which serum marker is the last to return to normal levels following a myocardial infarction?
- A. Lactate dehydrogenase (Correct Answer)
- B. Creatine phosphokinase
- C. Aspartate transaminase
- D. Myoglobin
Explanation: ### Explanation The correct answer is **Lactate dehydrogenase (LDH)**. Following a myocardial infarction (MI), cardiac enzymes are released into the bloodstream at different rates and durations, which is critical for retrospective diagnosis. **1. Why Lactate Dehydrogenase (LDH) is correct:** LDH is a "late marker" of myocardial injury. It begins to rise 10–24 hours after the onset of chest pain, peaks at 48–72 hours, and remains elevated for **7 to 14 days**. Because of its long half-life, it is the last of the traditional markers to return to baseline, making it useful for diagnosing an MI that occurred several days prior. Specifically, the LDH-1 isoenzyme rises above LDH-2 (the "flipped pattern"). **2. Why the other options are incorrect:** * **Myoglobin:** This is the **earliest marker** to rise (within 1–3 hours) but is highly non-specific and returns to normal within **24 hours**. * **Creatine Phosphokinase (CPK-MB):** This is the gold standard for detecting **re-infarction**. It rises within 4–8 hours, peaks at 24 hours, and returns to normal within **48–72 hours**. * **Aspartate Transaminase (AST):** AST rises within 8–12 hours and returns to normal within **3–5 days**, much sooner than LDH. **3. High-Yield Clinical Pearls for NEET-PG:** * **Earliest Marker:** Myoglobin. * **Most Specific Marker:** Cardiac Troponin I (cTnI). * **Marker for Re-infarction:** CK-MB (due to its rapid rise and fall). * **Troponin Duration:** Troponin T can stay elevated for up to 10–14 days (similar to LDH), but in the context of traditional enzyme options, LDH is the classic answer for the "last to return to normal." * **LDH Flipped Pattern:** In healthy individuals, LDH-2 > LDH-1. In MI, LDH-1 > LDH-2.
Question 8: A patient presents with unconjugated hyperbilirubinemia and presence of urobilinogen in urine. Which amongst the following is the least likely diagnosis?
- A. Hemolytic jaundice (Correct Answer)
- B. Crigler-Najjar syndrome type 1
- C. Gilbert's syndrome
- D. Crigler-Najjar syndrome type 2
Explanation: ### Explanation The question asks for the **least likely** diagnosis given a specific clinical triad: Unconjugated Hyperbilirubinemia (UCH) and the **presence of urobilinogen in urine**. #### 1. Why "Hemolytic Jaundice" is the Correct Answer (Least Likely) In **Hemolytic Jaundice**, there is an overproduction of bilirubin. The liver conjugates as much as possible, leading to increased stercobilinogen in the gut. This results in **increased** levels of urobilinogen being reabsorbed and excreted in the urine. Therefore, hemolytic jaundice **typically presents** with urinary urobilinogen. *Note: There appears to be a technical discrepancy in the provided key. In standard medical teaching, Hemolytic Jaundice, Gilbert’s, and Crigler-Najjar Type 2 all show urinary urobilinogen. However, in **Crigler-Najjar Type 1**, there is a **total absence** of UDP-glucuronosyltransferase activity. No conjugated bilirubin reaches the gut; thus, **no urobilinogen is formed**. If the question implies which condition is "least likely" to have urobilinogen, Type 1 is the classic answer. If the key marks Hemolytic Jaundice as correct, it suggests a focus on the "most likely" cause of the clinical picture, or a specific examiner preference regarding the magnitude of urobilinogen.* #### 2. Analysis of Other Options * **Gilbert’s Syndrome & Crigler-Najjar Type 2:** These involve partial deficiency of glucuronyltransferase. Some conjugation occurs; therefore, urobilinogen will be present in urine, making them likely diagnoses for the clinical stem. * **Crigler-Najjar Type 1:** This is the most severe form. Because conjugation is zero, urobilinogen is absent in urine. #### 3. NEET-PG High-Yield Pearls * **Urine Bilirubin:** Only conjugated bilirubin (water-soluble) appears in urine. It is **absent** in all unconjugated hyperbilirubinemias (hence "acholuric jaundice"). * **Urine Urobilinogen:** * **Increased:** Hemolytic Jaundice. * **Absent:** Obstructive Jaundice and Crigler-Najjar Type 1. * **Phenobarbital Test:** Helps differentiate Crigler-Najjar Type 2 (bilirubin levels decrease) from Type 1 (no response).
Question 9: Increased 5-hydroxyindoleacetic acid in urine is seen in which of the following conditions?
- A. Pheochromocytoma
- B. Ogilvie syndrome
- C. Carcinoid syndrome (Correct Answer)
- D. Tumor lysis syndrome
Explanation: **Explanation:** **Correct Answer: C. Carcinoid syndrome** The underlying medical concept here is the metabolism of **Serotonin (5-HT)**. Carcinoid tumors, typically arising from enterochromaffin cells in the midgut, overproduce serotonin. In the body, serotonin is metabolized by the enzyme **Monoamine Oxidase (MAO)** into **5-hydroxyindoleacetic acid (5-HIAA)**, which is then excreted in the urine. Therefore, a 24-hour urinary 5-HIAA test is the gold-standard biochemical marker for diagnosing and monitoring Carcinoid syndrome. **Analysis of Incorrect Options:** * **A. Pheochromocytoma:** This is a tumor of the adrenal medulla characterized by excess catecholamines (Epinephrine/Norepinephrine). The urinary markers for this condition are **Vanillylmandellic acid (VMA)** and **Metanephrines**, not 5-HIAA. * **B. Ogilvie syndrome:** Also known as acute colonic pseudo-obstruction, this is a clinical condition involving massive dilation of the colon without mechanical obstruction. It has no specific biochemical association with serotonin metabolism. * **D. Tumor lysis syndrome:** This occurs due to rapid breakdown of cancer cells. It is characterized by hyperuricemia (increased **Uric acid**), hyperkalemia, hyperphosphatemia, and hypocalcemia. **High-Yield Clinical Pearls for NEET-PG:** * **Dietary Caution:** Patients must avoid serotonin-rich foods (bananas, walnuts, pineapples, avocados) for 72 hours before the 5-HIAA test to prevent false positives. * **Pellagra Connection:** In Carcinoid syndrome, up to 60% of dietary **Tryptophan** is diverted to serotonin synthesis (normally only 1%). This leads to a deficiency in Niacin (Vitamin B3) production, potentially causing **Pellagra** (Dermatitis, Diarrhea, Dementia). * **Clinical Triad:** Flushing, Diarrhea, and Right-sided heart failure (Tricuspid regurgitation/Pulmonary stenosis).
Question 10: Quantitative assessment of liver function can be done by:
- A. Degree of transaminases
- B. Degree of alkaline phosphatase
- C. Degree of GGT
- D. Estimation of galactose elimination capacity (Correct Answer)
Explanation: ### Explanation **1. Why the correct answer is right:** Most routine Liver Function Tests (LFTs) are actually markers of **liver injury** (enzymes) rather than true function. **Galactose Elimination Capacity (GEC)** is a dynamic test that measures the functional metabolic capacity of the liver. Galactose is phosphorylated almost exclusively by the liver (via galactokinase). By administering a standardized dose of galactose and measuring its clearance from the blood, clinicians can quantitatively assess the **functional hepatocyte mass**. It is particularly useful in chronic liver disease to predict prognosis and surgical risk. **2. Why the incorrect options are wrong:** * **Options A, B, and C (Transaminases, ALP, GGT):** These are **static biochemical markers** of cellular damage or cholestasis. * **Transaminases (ALT/AST)** indicate hepatocellular necrosis (leakage from damaged cells). * **ALP and GGT** are markers of cholestasis or biliary tree injury. * Crucially, these levels do not correlate with the actual "work" the liver is doing; for example, in end-stage cirrhosis, transaminases may be near normal because there are few hepatocytes left to leak enzymes. **3. Clinical Pearls for NEET-PG:** * **True Liver Function Tests:** These measure synthesis or clearance. Examples include **Serum Albumin**, **Prothrombin Time (PT/INR)**, and **Bilirubin**. * **Dynamic Tests:** Besides GEC, other quantitative tests include the **Indocyanine Green (ICG) clearance test** and the **Aminopyrine breath test**. * **Best indicator of acute liver liver failure prognosis:** Prothrombin Time (PT). * **Best indicator of liver's synthetic function (chronic):** Serum Albumin. * **Specific marker for Alcoholism:** GGT (Gamma-Glutamyl Transferase).
Practice by Chapter
Liver Function Tests
Practice Questions
Kidney Function Tests
Practice Questions
Cardiac Markers and Enzymes
Practice Questions
Pancreatic Function Tests
Practice Questions
Glucose Tolerance Tests
Practice Questions
Lipid Profile and Cardiovascular Risk
Practice Questions
Tumor Markers
Practice Questions
Hormonal Assays and Interpretation
Practice Questions
Electrolytes and Acid-Base Balance Tests
Practice Questions
Cerebrospinal Fluid Analysis
Practice Questions
Point-of-Care Testing
Practice Questions
Quality Control in Clinical Biochemistry
Practice Questions
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free